Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a meaningful acquisition

COSM

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

Cosmos Health to monetize assets totaling $20M to strengthen balance sheet

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 millionProceeds could fund a meaningful acquisition</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cosmos Health announced it is monetizing non-core assets totaling about $20 million to bolster liquidity without disrupting core healthcare operations. The real estate, including CosmoFarm and Cana Laboratories, is valued at roughly $15 million and is largely mortgage-free, with options to sell, leaseback, or borrow against it. Proceeds could finance a meaningful acquisition or move to a net debt-free position, possibly narrowing the valuation gap.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Cosmos Health identifies about $20M in non-core liquid assets. Potential liquidity to fund growth without disrupting operations.</li><li>$15M real estate (CosmoFarm, Cana Labs) mortgage-free; options include sale, leaseback, or borrowing.</li><li>Monetization could strengthen the balance sheet and fund strategic initiatives, closing the valuation gap.</li><li>Company stays focused on core healthcare operations while unlocking value.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cosmos Health Inc. (COSM)</strong>: Primary driver; exploring monetization of non-core assets to raise liquidity (~$20M).</li><li><strong>Cana Laboratories S.A. (N/A)</strong>: Real estate assets include the Cana site; otherwise owned subsidiary with asset monetization potential.</li><li><strong>Sky Premium Life (N/A)</strong>: Brand asset within Cosmos&#039; diversified asset base; brand strength cited as part of growth.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The press release describes strategic asset monetization to strengthen the balance sheet and support growth opportunities, aligning with corporate-development pricing dynamics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Asset monetization progress could impact COSM&#039;s balance sheet and valuation.</li><li>Real estate value exceeding COSM&#039;s current market cap signals potential upside if monetized.</li><li>Debt reduction or acquisitions could drive multiple expansion.</li><li>Near-term earnings unchanged; catalyst is asset realization in coming quarters.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Identified liquidity assets total approximately $20 million.</li><li>Real estate component valued at roughly $15 million.</li><li>Assets include CosmoFarm distribution facility and Cana Laboratories manufacturing site.</li><li>Monetization options: sale, sale-and-leaseback, or borrowing.</li><li>Announcement date: June 4, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Asset monetization could unlock value and potentially re-rate COSM within 6–12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><ul><li>Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 million</li><li>Proceeds could fund a meaningful acquisition or eliminate debt entirely</li><li>Company remains fully committed to its core healthcare operations<br></br><br></br></li></ul>  <p>CHICAGO, June  04, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7JScNK2dENUDBfMksPlIQXufLm5CoONzTLcCPdD_BG5tojoTat_wf64yDYnJkgtreGNhlUeg8iEB9Mi9PsUxUSk22glExPaPRg3o4lAdL8E=" rel="nofollow" target="_blank"><strong><u>Cosmos Health Inc.</u></strong></a><strong> (&#34;Cosmos Health&#34; or the "Company")</strong> <a href="https://www.globenewswire.com/Tracker?data=2eOT44lmbaQN_vcNe8VPkzao7Qjew76sZXjRdPgtYEMwwspZLjLirYQ4LFYaSI2NIf-Tu--u4VHQ8XYWxe5jHG19bfxKlWyDqh0u7_RH9No=" rel="nofollow" target="_blank"><strong><u> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</u></strong></a>, a diversified, vertically integrated global healthcare group, today announced it is exploring the monetization of non-core assets, having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company&#39;s operational capabilities.</p>  <p>The Company is fully committed to its core healthcare operations and views these assets as non-core in the sense that they can be monetized to strengthen the balance sheet, fund strategic initiatives, and close the gap between intrinsic value and current market valuation.</p>  <p>The identified assets comprise, among others, wholly owned real estate — the CosmoFarm distribution facility and Cana Laboratories manufacturing site — independently valued at approximately $15 million, a large portion of which is free of any mortgage or financial encumbrance, with options including an outright sale, sale and leaseback, or borrowing against these assets. The market value of the real estate alone exceeds the Company&#39;s current market capitalisation. In addition, the Company holds digital assets, marketable securities, and other liquid assets as part of its broader treasury strategy, which are readily monetizable.</p>  <p><strong>Greg Siokas, CEO of Cosmos Health, stated: </strong>"We have built a highly diversified asset base at Cosmos Health — from contract manufacturing at Cana and wholesale distribution at CosmoFarm, to our rapidly growing proprietary brands including Sky Premium Life and C-Scrub, our 18 Series brand in the United States, and our AI-driven R&amp;D platform. In times like these, diversification is a source of strength. We believe we can unlock approximately $20 million from our tangible and liquid assets — a very significant amount relative to our current valuation. If we were to monetize these assets, we could pursue a meaningful acquisition or achieve a net debt-free position. We will do what is best for our shareholders."</p>  <p align="justify"><strong>About Cosmos Health Inc.<br></br></strong>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life&#xAE;, Mediterranation&#xAE;, bio-bebe&#xAE;, C-Sept&#xAE; and C-Scrub&#xAE;. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a href="https://www.globenewswire.com/Tracker?data=YBjv5uFXeDEdR7_YBjyj-2lGSl3Re9SvWMPPPPvJBZs04MVunp_TcGSzJrrn3vFKxomEEck46zwXkSl0LqKrTJT1WOhIjc8yfpmjpob5QGFGUSLjd8sID08xveeLdS30" rel="nofollow" target="_blank"><u>www.cosmoshealthinc.com</u></a>, <a href="https://www.globenewswire.com/Tracker?data=Y-MOiw6RsqjXHwmfo30xVDWgoyGaGGWHgQnqytISZjLBZtx3csmRqS5okzcIwrEjTSHeK3S7KULIyncEUhjuulTvgqzvLxYtVlTl4fz5kfo=" rel="nofollow" target="_blank"><u>www.skypremiumlife.com</u></a>, <a href="https://www.globenewswire.com/Tracker?data=YBjv5uFXeDEdR7_YBjyj-ypDbc-uKfZ8Oah2_s8ryxo2j0pzOdf_9b3BVs7KijDm5UtLQh1_TjCE5KD-XKXEsQ==" rel="nofollow" target="_blank"><u>www.cana.gr</u></a>, <a href="https://www.globenewswire.com/Tracker?data=AdBJAn1afKIxPV2_Nh_alKpLvLxhEj_iLnemLfpJjqWgKw2wvdDObdn2Pt2r4vyHCU7oYcg1o73hoA2QMcrxrVlx-eM70RXzCQAFKyZH4kI=" rel="nofollow" target="_blank"><u>www.zipdoctor.co</u></a>, <a href="https://www.globenewswire.com/Tracker?data=YBjv5uFXeDEdR7_YBjyj-xOGsGR86YlRlA5nWcL-O4p9nmpT3Xna18piiLZX4Yf8atD3DEhBtRPuxD19Y-aKQPYFWU_Rcf4cmQZNHfqMATc=" rel="nofollow" target="_blank"><u>www.cloudscreen.gr</u></a>, as well as <a href="https://www.globenewswire.com/Tracker?data=zadYodOsSK_ZR6Bl2kdOd7PrD948HzZwf0d3sRjZ6g_Bdej76-xa3dl6GoXGGTjaHvVOnGRJQsbEQ6lkOC3uEs2psMnxw-w90zKc1q5HP6GI5LvW0vvkax5C9WK4WuXZ" rel="nofollow" target="_blank"><u>LinkedIn</u></a> and <a href="https://www.globenewswire.com/Tracker?data=q2B6suRgYK0J91A9tAHFy__I0QP22MnF09BTnywlngLoxkKOSWaCX8TrKxKPiDTYWKkDA6kVBE_CSW1BVjbsz2_MQknks_96azzDykPCTXc=" rel="nofollow" target="_blank"><u>X</u></a>.</p>  <p align="justify"><strong>Forward-Looking Statements</strong><br></br>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (<a href="https://www.globenewswire.com/Tracker?data=Y-MOiw6RsqjXHwmfo30xVKR4bA7avc_bqr0gmR8uAynyP3ZknjJaXK7koa6q0mE28dZ1XNzvLCfiZuc8BixvJA==" rel="nofollow" target="_blank"><u>www.sec.gov</u></a>). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.</p>  <p align="justify"><strong>Investor Relations Contact:</strong><br></br>BDG Communications<br></br><a href="https://www.globenewswire.com/Tracker?data=6beDsnsD4x_ledbtM5rFBbex-3rChPbp6-m3S_H0gO1P5ZWHVUJ0417WCNjXvwRsi9Rf6GpOodxoHaoE_7pji7WugVyYkpPjlTAmfQrJEjFgsQOoI2oeCv1NVxf5jP71" rel="nofollow" target="_blank">cosm@bdgcommunications.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTczMTg5MiM3NjM2NjkyIzIyOTgwOTQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NmEyNzFhMjAtZTZmMS00OWFiLTkwOGEtYmMyOTRhMjU1NmE5LTEzMDk2NDQtMjAyNi0wNi0wNC1lbg==/tiny/Cosmos-Health-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4"><img src="https://ml.globenewswire.com/media/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4/small/cosmos-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Cosmos Health announced it is monetizing non-core assets totaling about $20 million to bolster liquidity without disrupting core healthcare operations. The real estate, including CosmoFarm and Cana Laboratories, is valued at roughly $15 million and is largely mortgage-free, with options to sell, leaseback, or borrow against it. Proceeds could finance a meaningful acquisition or move to a net debt-free position, possibly narrowing the valuation gap.

Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News